Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine glutamate injection vs ornithine aspartate injection in chronic liver disease with hyperammonemia
CTR20131217Phase 2Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arginine glutamate in hyperammonemia, chronic liver disease (CLD), sponsored by Yangtze River Pharmaceutical Group. Started Mar 2014; status: completed.
02
Drugs
arginine glutamate
03
Conditions
hyperammonemiachronic liver disease (CLD)
Beyond the preview
Go deeper on CTR20131217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131217.